Similar Posts
Webinar – How to Treat Locoregional Reccurent Disease of Nasopharyngeal Cancer
Speakers: 1. dr. Raymond King-Yin TSANG, MBChB, MS, FRCSEd, FRCSEd(ORL), FHKCORL, FHKAM(Otorhinolaryngology) as Head of the Division of Otorhinolaryngology of the…
Daiichi Sankyo Enrolls First Patient in Nimotuzumab Phase 3 Clinical Trials
Tokyo, Japan (April 25, 2013) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that the first patient has been enrolled in…
July 2015: Innokeys Pte Ltd Consolidates Nimotuzumab Development by Acquiring Oncoscience AG
Innokeys Pte Ltd Consolidates Nimotuzumab Development by Acquiring Oncoscience AG • The acquisition enables Innokeys to fully lead clinical and commercial development…
ASCO 2013 : Nimotuzumab Abstracts
Professor Dirk Strumberg from Germany (center, in blue suit), the principal investigator of phase IIB/IIIA nimotuzumab clinical trial on pancreatic cancer, in…
August 2013: Nimotuzumab in MOGA Australia
Medical Oncology Group of Australia
New Marketing Authorization Approval in Myanmar for locally advanced unresectable or metastatic pancreatic cancer
New marketing authorization for indication locally advanced unresectable or metastatic pancreatic cancer is approved in Myanmar by the Myanmar FDA. This indication…